Purinergic (P2X) Receptors
P2X purinergic receptors are ATP-gated ion channels composed of three subunits, which confer specific receptor subtype pharmacology, and are permeable to cations. Binding of ATP results in channel opening, cation influx and membrane depolarization. These receptors are widely distributed throughout the body, and most cell types express more than one P2X receptor subtype. P2X receptors play physiological roles in a wide range of processes such as modulation of synaptic transmission, vascular tone, cardiac rhythm and contractility, immune response.
Purinergic (P2X) Receptor Agonists |
|
---|---|
Cat. No. | Product Name / Activity |
3245 | ATP disodium salt |
Endogenous P2 purinergic agonist | |
4080 | ATPγS tetralithium salt |
Non-selective P2 agonist; analog of ATP (Cat. No. 3245) | |
3312 | BzATP triethylammonium salt |
P2X7 agonist; also P2X1 and P2Y1 partial agonist | |
3209 | α,β-Methyleneadenosine 5'-triphosphate trisodium salt |
Non-selective P2 agonist | |
1062 | 2-Methylthioadenosine triphosphate tetrasodium salt |
Non-selective P2 agonist | |
Purinergic (P2X) Receptor Antagonists |
|
Cat. No. | Product Name / Activity |
6493 | A 317491 sodium salt |
Selective, high affinity P2X3 and P2X2/3 antagonist; antinociceptive | |
2972 | A 438079 hydrochloride |
Competitive P2X7 antagonist | |
3701 | A 740003 |
Potent and selective P2X7 antagonist | |
4473 | A 804598 |
Potent and selective P2X7 antagonist | |
3323 | AZ 10606120 dihydrochloride |
Potent P2X7 antagonist | |
3317 | AZ 11645373 |
Potent and selective human P2X7 antagonist | |
7573 | BAY 1797 |
Selective P2X4 antagonist | |
3579 | 5-BDBD |
Potent and selective P2X4 antagonist | |
5545 | BX 430 |
Selective P2X4 allosteric antagonist | |
0845 | Evans Blue tetrasodium salt |
P2X antagonist; also non-NMDA iGluR antagonist; inhibits L-glutamate uptake into synaptic vesicles | |
2611 | IMD 0354 |
P2X1, P2X4 and P2X7 antagonist; also inhibitor of IKKβ | |
5299 | JNJ 47965567 |
Potent and selective P2X7 antagonist; brain penetrant | |
1277 | KN-62 |
Non-competitive P2X7 antagonist | |
1240 | NF 023 |
Selective and competitive P2X1 antagonist | |
2548 | NF 110 |
Potent P2X3 antagonist | |
2450 | NF 157 |
Selective P2Y11 and P2X1 antagonist | |
1199 | NF 279 |
Potent and selective P2X1 antagonist | |
1391 | NF 449 |
Highly selective P2X1 antagonist | |
0625 | PPADS tetrasodium salt |
Non-selective P2 antagonist | |
0683 | iso-PPADS tetrasodium salt |
Non-selective P2X antagonist | |
4391 | Ro 51 |
Potent P2X3 and P2X2/3 antagonist | |
3052 | RO-3 |
Selective P2X3 and P2X2/3 antagonist | |
1472 | Suramin hexasodium salt New |
Non-selective P2 antagonist | |
2464 | TNP-ATP triethylammonium salt |
Potent and selective P2X antagonist | |
Purinergic (P2X) Receptor Modulators |
|
Cat. No. | Product Name / Activity |
1260 | Ivermectin |
Positive allosteric modulator of P2X4 receptors | |
Other |
|
Cat. No. | Product Name / Activity |
5157 | DMNPE-caged ATP diammonium salt |
Caged ATP |
P2X Purinergic Receptor Subunits
Each functional P2X receptor is formed from either three identical subunits (homomeric) or a combination of two or three different subunits (heteromeric). Except for P2X6, all subunits can form homomeric receptors, however, P2X7 subunits only form homomeric receptors. Functional receptors are named for their constituent subunits, for example a homomeric receptor composed of P2X7 subunits is called a P2X7 receptor, while a heteromeric receptor composed of P2X2 and P2X3 subunits is called a P2X2/3 receptor.
Figure 1: Structure of human homomeric P2X3 receptor. Structure taken from PDB. PDBID: 5SVQ. Mansoor et al (2016) X-ray structures define human P2X3 receptor gating cycle and antagonist action. Nature 538: 66-71
Three molecules of ATP are required for channel opening, with one binding to each subunit. P2X receptors are highly selective for ATP over other purines and pyrimidines such as ADP and UTP, which activate P2Y receptors. ATP binding causes a conformational change in the ion channel structure that opens the pore and allows cations to pass through the cell membrane. The specific subunit confirmation of a receptor determines channel opening time; for example P2X1 and P2X3 receptors desensitize within a few 100 ms but for P2X7 receptors there is little decrease in ionic current flow even over several minutes.
The subunit conformation of a receptor also determines its pharmacology; different subunits have different sensitivities to P2X agonists, such as ATP (Cat. No. 3245) and α,β-meATP (Cat. No. 3209) and P2X antagonists, such as PPADS (Cat. No 0625) and TNP-ATP (Cat. No. 2464). The sensitivity of a P2X receptor to ATP is heavily affected by changes in extracellular pH and by heavy metals, due to the presence of histidine side chains in the receptor's extracellular domains. An extracellular pH <7 attenuates ATP sensitivity at P2X1, P2X3 and P2X4 receptors but increases P2X2 receptor ATP sensitivity. In contrast, zinc potentiates ATP-gated currents through P2X2, P2X3 and P2X4, and inhibits currents through P2X1 receptors.
P2X Purinergic Receptor Distribution
P2X receptors have a wide distribution throughout the body and are found at neuromuscular junctions in the central and peripheral nervous system including the spinal cord, in smooth muscle, in the heart, and on leukocytes. In the brain, P2X receptors are found at pre- and post-synaptic membranes where they modulate neurotransmitter release. In general, different P2X receptor subtypes don't display tissue specificity and there is a large overlap in subunit distribution, with most cells expressing more than one receptor subtype.
Their extensive distribution means P2X receptors are involved in a diverse range of physiological processes, including modulation of synaptic transmission, modulation of vascular tone, cardiac rhythm and contractility, nociception and chronic pain, contraction of the bladder, and immune response.
P2X7 receptors are of interest in cancer immunology as they are overexpressed in tumors. Elevated intratumoral ATP levels acting via P2X7 receptors on myeloid-derived suppressor cells (MDSCs), result in immunosuppression.
P2X Purinergic Receptors & Nociception
P2X3 and P2X2/3 receptors have been well studied for their role in nociception. They are highly expressed on sensory neurons in dorsal root ganglia in the spinal cord, and are also found at nociceptive nerve terminal in the periphery where they respond to increased extracellular ATP from various sources including tumors and the vascular endothelium. Similarly, activation of P2X and P2Y receptors on glial cells (astrocytes and microglial) are thought to indirectly modulate nociception. Research has suggested that the expression of these receptors on nociceptive nerve terminals and glial cells contributes to the development and maintenance of various forms of neuropathic and inflammatory pain. The selective P2X2 and P2X2/3 receptor antagonist A 317491 (Cat. No. 6493) displays antinociceptive activity in multiple different pain paradigms including neuropathic, inflammatory and chronic pain states, in animal models.
External sources of pharmacological information for Purinergic (P2X) Receptors :
Literature for Purinergic (P2X) Receptors
Tocris offers the following scientific literature for Purinergic (P2X) Receptors to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
P2X Receptor Gene Data
Gene | Species | Gene Symbol | Gene Accession No. | Protein Accession No. |
---|---|---|---|---|
P2X1 | Human | P2RX1 | NM_002558 | P51575 |
Mouse | P2rx1 | NM_008771 | P51576 | |
Rat | P2rx1 | NM_012997 | P47824 | |
P2X2 | Human | P2RX2 | NM_174873 | Q9NR38 |
Mouse | P2rx2 | NM_153400 | NP_700449 | |
Rat | P2rx2 | NM_053656 | P49653 | |
P2X3 | Human | P2RX3 | NM_002559 | P56373 |
Mouse | P2rx3 | NM_145526 | Q3UR32 | |
Rat | P2rx3 | NM_031075 | P49654 | |
P2X4 | Human | P2RX4 | NM_175567 | Q99571 |
Mouse | P2rx4 | NM_011026 | Q9JJX6 | |
Rat | P2rx4 | NM_031594 | P51577 | |
P2X5 | Human | P2RX5 | NM_002561 | Q93086 |
Mouse | P2rx5 | NM_033321 | NP_201578 | |
Rat | P2rx5 | NM_080780 | P51578 | |
P2X6 | Human | P2RX6 | NM_005446 | O15547 |
Mouse | P2rx6 | NM_011028 | O54803 | |
Rat | P2rx6 | NM_012721 | P51579 | |
P2X7 | Human | P2RX7 | NM_002562 | Q99572 |
Mouse | P2rx7 | NM_011027 | Q9Z1M0 | |
Rat | P2rx7 | NM_019256 | Q64663 |